SYLVIE FAUCONNET

Dr. SYLVIE FAUCONNET

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
GBGuillaume Boiteux
Guillaume Boiteux
ILIsabelle Lascombe
Isabelle Lascombe
EREmmanuelle Roche
Emmanuelle Roche
MPMarie-Laure Plissonnier
Marie-Laure Plissonnier
ACAnne Clairotte
Anne Clairotte
SFSYLVIE FAUCONNET
SYLVIE FAUCONNET
Superficial pT1 bladder tumors are characterized by a high risk of recurrence and progression in grade and stage. Few studies provided evidence that loss of adipocyte‐fatty acid binding protein (A‐FABP) expression was associated with bladder cancer progression. A‐FABP is a lipid binding protein playing a role in intracellular lipid transport and metabolism, as well as in signal transduction. We reported from bladder tumors that decrease of A‐FABP transcript level significantly correlated to tumor stage and to histologic grade (p < 0.05). Namely, in poor prognosis high grade pT1 tumors there was a loss of A‐FABP expression compared to good prognosis tumors suggesting that re‐expression of A‐FABP could be a therapeutic approach in early stage bladder cancer to prevent disease progression. We demonstrated for the first time that this marker is upregulated by Peroxisome Proliferator‐Activated Receptor (PPAR) α, β and γ in T24 cells (derived from an undifferentiated grade III carcinoma) and only by PPARβ in RT4 cells (derived from a well differentiated grade I papillary tumor). This effect occurred through a PPAR‐dependent transcriptional mechanism without modifying mRNA stability and interestingly required de novo protein synthesis. Data as a whole suggest a prognostic significance of A‐FABP in bladder cancer outcome and the potential utility of overexpression of this protein by PPAR agonists open up new perspectives in the treatment of bladder cancer.

6 May 2009 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
SFSYLVIE FAUCONNET
SYLVIE FAUCONNET
The present investigation was conducted first to determine whether correlation exists between VEGF-A and -B mRNA levels and clinicopathological parameters and to assess their prognostic value in bladder cancer, then to clarify the expression level and biological significance of VEGF-A isoforms. Total RNA was isolated from 37 specimens of bladder cancer. Northern blot analysis revealed that VEGF-B mRNA was not expressed either in normal urothelium or in bladder cancer and detected three VEGF-A transcripts of 5.2, 4.5 and 1.7 kb in length, respectively. The VEGF-A transcript levels were greater in cancer tissues than in normal urothelium. They were significantly higher in pT2-T4 than in pTa and pT1 urothelial tumors and thus, were correlated to the pathologic stage. Contrary to the 4.5 kb transcript, elevated expression of the 5.2 and 1.7 kb transcripts was correlated with the histologic grade and the presence of carcinoma in situ. Patients with higher VEGF-A mRNA levels had a significantly shorter survival without progression compared to those with lower levels. Three VEGF-A splice variants were detected by southern blotting namely, VEGF121, 165 and 189. The expression intensity of each isoform was evaluated by quantitative real-time RT-PCR in 20 new fresh frozen recent tumors. VEGF121 and VEGF165 were expressed at the similar level. On the contrary, they were significantly more expressed than VEGF189 (p<0.05). The three isoforms were higher expressed in pT2 bladder cancers than in pTa tumors (p<0.05). There was only a significant correlation between the increased expression level of VEGF121 and 165 and the histological grade of the lesion (p<0.05). To conclude, VEGF-A mRNA level is a potential prognostic indicator of progression in bladder cancer as well as the expression level of the different VEGF-A splice variants.

10 December 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
CMChristel Mathis
Christel Mathis
ILIsabelle Lascombe
Isabelle Lascombe
FMFranck Monnien
Franck Monnien
HBHugues Bittard
Hugues Bittard
FKFrançois Kleinclauss
François Kleinclauss
SVSéverine Valmary-Degano
Séverine Valmary-Degano
Non-muscle invasive bladder cancers (NMIBC: pTa, pT1) are characterised by a high risk of recurrence and/or progression. Identification of prognostic markers is needed to improve both diagnosis and management of the disease. The aim of this study was to analyse the expression of A-FABP (adipocyte-fatty acid binding protein) and to evaluate its prognostic value in bladder cancer with a long term clinical follow-up. A-FABP expression was investigated by immunohistochemistry in 236 tumours (114 pTa, 61 pT1, 61 pT2–4). Immunostaining was classified as negative (absent or weak immunostaining and moderate or strong staining on ≤10% of cells) or positive (moderate or strong staining on > 10% of cells). Event-free survival (EFS) and overall survival (OS) were determined with a 87.3 months median follow-up in the overall cohort. Recurrence-free survival (RFS) and progression-free survival (PFS) were established in NMIBC. Loss of A-FABP was associated with higher mean age, high stage/grade, and the presence of metastatic lymph nodes. It was correlated with shorter median EFS (17.5 vs 62.5 months; p = 0.001) and mean OS (76.7 vs 154.2 months; p = 0.009) and with higher risk of progression in the pTa/pT1 subgroup (HR, 0.36; 95% CI, 0.13–0.96; p = 0.041) and importantly in the pTa tumours (HR, 0.34; 95% CI, 0.10–0.97; p = 0.045). These results demonstrated that loss of A-FABP expression following a long follow-up was predictive of pTa and pTa/pT1 progression. Immunohistochemistry on diagnostic biopsy is easy to use and could be of value to help clinicians to propose appropriate treatment for these tumours.

9 June 2020 in Molecular and Cellular Biochemistry
Verified
Journal Article
Open access
PDF file
CECéline Elie-Caille
Céline Elie-Caille
ILIsabelle Lascombe
Isabelle Lascombe
APAdeline Péchery
Adeline Péchery
HBHugues Bittard
Hugues Bittard
SFSYLVIE FAUCONNET
SYLVIE FAUCONNET
N-cadherin is a transmembrane glycoprotein expressed by mesenchymal origin cells and is located at the adherens junctions. It regulates also cell motility and contributes to cell signaling. In previous studies, we identified that its anomalous expression in bladder carcinoma was a tumor progression marker. A pharmacological approach to inhibit N-cadherin expression or to block its function could be relevant to prevent disease progression and metastasis development. The morphological exploration of T24 invasive bladder cancer cells by atomic force microscopy (AFM) revealed a spindle-like shape with fibrous structures. By engaging force spectroscopy with AFM tip functionalized with anti-E or anti-N-cadherin antibodies, results showed that T24 cells expressed only N-cadherin as also demonstrated by Western blotting and confocal microscopy. For the first time, we demonstrated by RTqPCR and Western blotting analyses that the peroxisome proliferator-activated receptor β/δ (PPARβ/δ) agonist GW501516 significantly decreased N-cadherin expression in T24 cells. Moreover, high non-cytotoxic doses of GW501516 inhibited confluent T24 cell wound healing closure. By using AFM, a more sensitive nanoanalytical method, we showed that the treatment modified the cellular morphology and diminished N-cadherin cell surface coverage through the decreasing of these adhesion molecule-mediated interaction forces. We observed a greater decrease of N-cadherin upon GW501516 exposure with AFM than that detected with molecular biology techniques. AFM was a complementary tool to biochemical techniques to perform measurements on living cells at the nanometer resolution level. Taken together, our data suggest that GW501516 could be an interesting therapeutic strategy to avoid bladder cancer cell spreading through N-cadherin decrease.

1 May 2021 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
LCLidia Cabeza
Lidia Cabeza
BRBahrie Ramadan
Bahrie Ramadan
JGJulie Giustiniani
Julie Giustiniani
CHChristophe Houdayer
Christophe Houdayer
YPYann Pellequer
Yann Pellequer
YPYvan PETERSCHMITT
Yvan PETERSCHMITT

1 January 1992 in Biology of the Cell
Verified
Journal Article
Closed access
PDF file
AMAbderrahim Mahfoudi
Abderrahim Mahfoudi
SFSYLVIE FAUCONNET
SYLVIE FAUCONNET
JBJacqueline Bride
Jacqueline Bride
LBLaurent Beck
Laurent Beck
JRJean‐Paul Remy‐Martin
Jean‐Paul Remy‐Martin
GAGerard L Adessi
Gerard L Adessi